A Phase 2 interventional study of ASLAN003 in Acute Myeloid Leukemia, sponsored by ASLAN Pharmaceuticals. Completed at 8 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-07-06.
Sponsored by ASLAN Pharmaceuticals · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 148 studies in Leukemia, Myeloid, Acute with a site in Australia — 23 open to participants now, 45 under way, 17 of them phase 3. Leukemia, Myeloid, Acute · Australia.
Among the 148 studies in Leukemia, Myeloid, Acute with a site in Australia, this one is the 124th largest by enrollment of the 144 interventional ones that give a count, is one of 15 that started in 2018, is one of 19 in phase 2, and was the 72nd registered.
3,672 studies on the registry are indexed under Leukemia, Myeloid, Acute; 812 are open to participants now.
Browse Leukemia, Myeloid, Acute studies →23 of the 148 studies in Leukemia, Myeloid, Acute with a site in Australia are open now. Recruiting first, the newest first:
AbbVie · Sites in Australia, United States, France and 4 more countries
Ages 6 mo–17 yrs
Stichting Hemato-Oncologie voor Volwassenen Nederland · Sites in Australia, United States, Austria and 10 more countries
Ages 18+
AstraZeneca · Sites in Australia, United States, Canada and 6 more countries
Ages 16+
Syndax Pharmaceuticals · Sites in Australia, United States, Argentina and 20 more countries
Ages 12+
Kura Oncology, Inc. · Sites in Australia, United States, Belgium and 14 more countries
Ages 18+
A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →
Of the 617 Leukemia, Myeloid, Acute studies recruiting now, 359 (58%) set no upper age limit and 219 (35%) stop at 75 or younger; 144 take children under 18; 29 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
148 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 74 · Phase 2 41 · Phase 3 48 · Phase 4 1
First in 1997; this study’s year is marked. 15 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 24 is below the median of 40 across 3,010 interventional studies indexed under Leukemia, Myeloid, Acute.
Median enrollment 108 across the 144 interventional studies, 25 across the 3 observational. Of the 95 that completed or were terminated, 50 (53%) have results posted.
This tab as a report to print or save as PDF → With an account.
113 of 148 have an industry lead sponsor. The 10 most frequent:
ASLAN Pharmaceuticals is the lead sponsor of 20 studies on the registry; 2 are open to participants now.
ASLAN Pharmaceuticals has 1 study filed under Leukemia, Myeloid, Acute — fewer than ten, so there is no comparison to draw.
9 of the studies in Leukemia, Myeloid, Acute with a site in Australia that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05183035Phase 3PedAL BCU, LLCVenetoclax in Children With Relapsed Acute Myeloid Leukemia (AML) | 2027-02 |
| NCT03839771Phase 3Stichting Hemato-Oncologie voor Volwassenen NederlandA Study of Ivosidenib or Enasidenib in Combination With Induction Therapy and Consolidation Therapy, Followed by Maintenance Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myedysplastic Syndrome EB2, With an IDH1 or IDH2 Mutation, Respectively, Eligible for Intensive Chemotherapy | 2027-04-17 |
| NCT03844048Phase 3AbbVieAn Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial | 2027-08 |
| NCT03850574Aptose Biosciences Inc.Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia | 2026-11 |
| NCT05659732PharmaEngineA Study of PEP07 (Checkpoint Kinase 1 Inhibitor) in Patients With Advanced Cancer | 2026-12-31 |
Add all 9 to your calendar (.ics) → With an account.
Among the 148 studies in Leukemia, Myeloid, Acute with a site in Australia, from their registry updates:
This tab as a report to print or save as PDF → With an account.
ASLAN003-003 is a multi-center, Phase IIA study to evalute the efficacy of ASLAN003 in AML patients who are ineligible for standard treatment with an expansion cohort in relapsed/refractory patients, and to determine the appropriate dose of ASLAN003 in combination with azacitidine in older (more than or equal to 60 years) AML patients who have exhausted any approved and available treatment options.
ASLAN003-003 is a multi-center, Phase IIA study to determine the optimum dose of ASLAN003 based on the safety, efficacy, and tolerability of varying doses of ASLAN003 (100 mg QD, 200 mg QD, 100 mg BID, and possibly 200 mg BID) administered to AML subjects daily for a continuous 28-day treatment cycle until disease relapse, disease progression, unacceptable toxicity, or withdrawal of consent.
The study has 2 parts and plans to enroll a total of 44 to 56 patients with 18 to 24 patients in Part 1 and 26 to 32 patients in Part 2 (comprising Parts 2A and 2B). The Overall Complete Remission Rate will be evaluated in AML patients not eligible for standard treatment (Part 1) and in relapsed and refractory AML patients (Part 2A) using the optimum dose of ASLAN003 established in Part 1 of the study. In Part 2B of the study, the appropriate dose of ASLAN003 in combination with azacitidine in older (more than or equal to 60 years) AML patients who have exhausted any approved and available treatment options will be determined.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Note: Patients who do not have sufficient archival BM aspiration sample and refuse to repeat the procedure may be enrolled in the trial only after written confirmation by ASLAN 5. Part 1: Patients who are ineligible for standard treatment of AML including to the following conditions:
Patients who have failed to respond to prior therapy including chemotherapy, hypomethylating agents, and bone marrow transplantation.
Refractory patients who have no CR or CRi after 2 courses of intensive induction treatment 5. Part 2B: Older patients (more than or equal to 60 years) AML patients who have exhausted any approved and available treatment options.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: ASLAN003
Drug: ASLAN003
Drug: ASLAN003
Drug: ASLAN003
Drug: ASLAN003
Drug: ASLAN003
Patients will be administered with the study drug, ASLAN003. The study drug is to be administered orally, QD or BID. It is recommended to administer the study drug with food or within 30 minutes after food intake.
Overall Complete Remission Rate
Defined as the proportion of patients with a best response of complete remission (CR) or complete remission with incomplete hematologic recovery (CRi), defined in accordance with the IWG Response Criteria in AML from day 29. Treatment failure is defined as not achieving any response 4 months after study treatment. IWG Response Criteria in AML defines CR or CRi as: 1. Complete remission (CR): Bone marrow blasts \<5 percent; absence of blasts with Auer rods; absence of extramedullary disease; absolute neutrophil count \>1.0 x 109/L (1000/µL); platelet count \>100 x 109/L (100,000/µL); independence of red cell transfusions 2. CR with incomplete recovery (CRi): All CR criteria except for residual neutropenia (\<1.0 x 109/L (1000/µL)) or thrombocytopenia (\<100 x 109/L (100,000/µL))
Time frame: 4 months after study treatment
Number of Participants With Adverse Events
Number of Participants with Adverse Events reported through 28 days post last study medication administration
Time frame: Through 28 days post last study medication administration
Safety Assessments
Safety Assessments - Clinical laboratory test: Hematology and Chemistry
Time frame: Through 28 days post last study medication administration
Relapse Free Survival
Defined as the time the criteria for remission (CR or CRi) are first met until there is evidence of patient relapse, regardless of whether the patient is still taking study drug. Relapse is defined as: * The reappearance of leukemic blasts in the peripheral blood or \> 5% blasts in the bone marrow not attributable to any other cause; * The appearance of new dysplastic changes; * The reappearance of or development of cytologically proven extrameduallary disease; * The reappearance of a cytogenetic or molecular abnormality.
Time frame: From 12 weeks post end of treatment (EOT) until the date of first documented relapse or date of death from any cause, whichever came first, assessed up to 24 months
Clinical Benefit Rate
Defined as the proportion of subjects with an AML IWG best response of CR, CRi or PR. IWG Response Criteria in AML defines CR, CRi or PR as: 1. Complete remission (CR): Bone marrow blasts \<5 percent; absence of blasts with Auer rods; absence of extramedullary disease; absolute neutrophil count \>1.0 x 109/L (1000/µL); platelet count \>100 x 109/L (100,000/µL); independence of red cell transfusions 2. CR with incomplete recovery (CRi): All CR criteria except for residual neutropenia (\<1.0 x 109/L (1000/µL)) or thrombocytopenia (\<100 x 109/L (100,000/µL)) 3. Partial remission (PR): All hematologic criteria of CR; decrease of bone marrow blast percentage to 5 to 25 percent; and decrease of pre-treatment bone marrow blast percentage by at least 50 percent
Time frame: 4 months after study treatment
% Change From Baseline in BM Blasts at Day 29
Percent Change from Baseline in BM Blasts at Day 29
Time frame: Baseline and day 29
| Milestone | Part 1: ASLAN003 100mg QD | Part 1: ASLAN003 200mg QD | Part 1: ASLAN003 100mg BID | Part 1: ASLAN003 200mg BID |
|---|---|---|---|---|
| Started | 6 | 6 | 6 | 6 |
| Completed | 0 | 0 | 0 | 0 |
| Not completed | 6 | 6 | 6 | 6 |
| Withdrew: Withdrawal by subject | 2 | 1 | 2 | 1 |
| Withdrew: Disease recurrence | 0 | 2 | 0 | 0 |
| Withdrew: Lack of efficacy | 0 | 3 | 0 | 1 |
| Withdrew: Death | 1 | 0 | 2 | 0 |
| Withdrew: Physician decision | 0 | 0 | 2 | 2 |
| Withdrew: Disease progression (n=4), study closed by sponsor (n=1) | 3 | 0 | 0 | 2 |
Defined as the proportion of patients with a best response of complete remission (CR) or complete remission with incomplete hematologic recovery (CRi), defined in accordance with the IWG Response Criteria in AML from day 29. Treatment failure is defined as not achieving any response 4 months after study treatment. IWG Response Criteria in AML defines CR or CRi as: 1. Complete remission (CR): Bone marrow blasts \<5 percent; absence of blasts with Auer rods; absence of extramedullary disease; absolute neutrophil count \>1.0 x 109/L (1000/µL); platelet count \>100 x 109/L (100,000/µL); independence of red cell transfusions 2. CR with incomplete recovery (CRi): All CR criteria except for residual neutropenia (\<1.0 x 109/L (1000/µL)) or thrombocytopenia (\<100 x 109/L (100,000/µL))
| Participants | Part 1: ASLAN003 100mg QD | Part 1: ASLAN003 200mg QD | Part 1: ASLAN003 100mg BID | Part 1: ASLAN003 200mg BID |
|---|---|---|---|---|
| Responders | 0 | 0 | 0 | 0 |
| Treatment Failure | 2 | 4 | 2 | 6 |
| Non-evaluable | 4 | 0 | 4 | 0 |
Number of Participants with Adverse Events reported through 28 days post last study medication administration
| participants | Part 1: ASLAN003 100mg QD | Part 1: ASLAN003 200mg QD | Part 1: ASLAN003 100mg BID | Part 1: ASLAN003 200mg BID |
|---|---|---|---|---|
| Number of Patients with Any TEAE | 5 | 6 | 6 | 6 |
| Number of Patients with Any TEAE related to study treatment | 3 | 4 | 1 | 4 |
| Number of Patients with Any TEAE CTCAE grade 3 or higher | 5 | 5 | 6 | 6 |
| Number of Patients with Any TEAE CTCAE grade 3 or higher related to study treatment | 2 | 2 | 1 | 2 |
| Number of Patients with Any TEAE with outcome of death | 0 | 1 | 0 | 0 |
| Number of Patients with Any TEAE with outcome of death related to study treatment | 0 | 0 | 0 | 0 |
| Number of Patients with Any serious TEAE | 3 | 5 | 4 | 6 |
| Number of Patients with Any serious TEAE related to study treatment | 0 | 0 | 0 | 1 |
| Number of Patients with Any TEAE leading to discontinuation of study therapy | 0 | 0 | 1 | 0 |
| Number of Patients with Any TEAE leading to discontinuation of study therapy related to treatment | 0 | 0 | 0 | 0 |
Safety Assessments - Clinical laboratory test: Hematology and Chemistry
| participants | Part 1: ASLAN003 100mg QD | Part 1: ASLAN003 200mg QD | Part 1: ASLAN003 100mg BID | Part 1: ASLAN003 200mg BID |
|---|---|---|---|---|
| Hematology - Abnormal white blood cell counts reported by Investigator as AEs of leukocytosis | 2 | 3 | 3 | 0 |
| Hematology - Abnormal/decreased hemoglobin values reported by Investigator as AEs of anaemia | 3 | 1 | 2 | 2 |
| Hematology - Abnormal neutrophil count reported by Investigator as AE of neutropenia | 0 | 0 | 0 | 1 |
| Hematology - Abnormal neutrophil counts reported by Investigator as AEs febrile neutropenia | 0 | 1 | 0 | 2 |
| Hematology - Abnormal/decreased platelet count reported by Investigator as AEs of thrombocytopenia | 2 | 0 | 2 | 1 |
| Chemistry - Abnormal serum potassium values reported by Investigator as AEs of hypokalaemia | 2 | 3 | 2 | 1 |
| Chemistry - Elevated levels of serum glucose reported by Investigator as AEs of hyperglycaemia | 1 | 1 | 0 | 0 |
| Chemistry - Abnormal blood creatinine reported by Investigator as AE of blood creatinine increased | 0 | 0 | 1 | 0 |
Defined as the time the criteria for remission (CR or CRi) are first met until there is evidence of patient relapse, regardless of whether the patient is still taking study drug. Relapse is defined as: * The reappearance of leukemic blasts in the peripheral blood or \> 5% blasts in the bone marrow not attributable to any other cause; * The appearance of new dysplastic changes; * The reappearance of or development of cytologically proven extrameduallary disease; * The reappearance of a cytogenetic or molecular abnormality.
No measurements were reported for this outcome.
Defined as the proportion of subjects with an AML IWG best response of CR, CRi or PR. IWG Response Criteria in AML defines CR, CRi or PR as: 1. Complete remission (CR): Bone marrow blasts \<5 percent; absence of blasts with Auer rods; absence of extramedullary disease; absolute neutrophil count \>1.0 x 109/L (1000/µL); platelet count \>100 x 109/L (100,000/µL); independence of red cell transfusions 2. CR with incomplete recovery (CRi): All CR criteria except for residual neutropenia (\<1.0 x 109/L (1000/µL)) or thrombocytopenia (\<100 x 109/L (100,000/µL)) 3. Partial remission (PR): All hematologic criteria of CR; decrease of bone marrow blast percentage to 5 to 25 percent; and decrease of pre-treatment bone marrow blast percentage by at least 50 percent
No measurements were reported for this outcome.
Percent Change from Baseline in BM Blasts at Day 29
| Percentage change | Part 1: ASLAN003 100mg QD | Part 1: ASLAN003 200mg QD | Part 1: ASLAN003 100mg BID | Part 1: ASLAN003 200mg BID |
|---|---|---|---|---|
| % Change From Baseline in BM Blasts at Day 29 | -34.43 | -8.33 | — | — |
Collected over From the time of informed consent and until 28 days after the last administration of study drug, up to 24 months.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part 1: ASLAN003 100mg QD | 6/6 (100%) | 3/6 (50%) | 3/6 (50%) |
| Part 1: ASLAN003 200mg QD | 6/6 (100%) | 5/6 (83.3%) | 4/6 (66.7%) |
| Part 1: ASLAN003 100mg BID | 6/6 (100%) | 4/6 (66.7%) | 1/6 (16.7%) |
| Part 1: ASLAN003 200mg BID | 3/6 (50%) | 6/6 (100%) | 4/6 (66.7%) |
| Event | Part 1: ASLAN003 100mg QD | Part 1: ASLAN003 200mg QD | Part 1: ASLAN003 100mg BID | Part 1: ASLAN003 200mg BID |
|---|---|---|---|---|
| Febrile neutropeniaBlood and lymphatic system disorders | 0/6 | 1/6 | 0/6 | 3/6 |
| PneumoniaInfections and infestations | 2/6 | 1/6 | 2/6 | 0/6 |
| Respiratory syncytial virus infectionInfections and infestations | 1/6 | 1/6 | 0/6 | 0/6 |
| Anal abscessInfections and infestations | 0/6 | 0/6 | 0/6 | 1/6 |
| Lymph node abscessInfections and infestations | 0/6 | 0/6 | 0/6 | 1/6 |
| Pathogen resistanceInfections and infestations | 1/6 | 0/6 | 0/6 | 0/6 |
| Pulmonary sepsisInfections and infestations | 0/6 | 0/6 | 0/6 | 1/6 |
| SepsisInfections and infestations | 0/6 | 0/6 | 1/6 | 0/6 |
| Urinary tract infectionInfections and infestations | 0/6 | 0/6 | 1/6 | 0/6 |
| ThrombocytopeniaBlood and lymphatic system disorders | 0/6 | 0/6 | 1/6 | 0/6 |
| Event | Part 1: ASLAN003 100mg QD | Part 1: ASLAN003 200mg QD | Part 1: ASLAN003 100mg BID | Part 1: ASLAN003 200mg BID |
|---|---|---|---|---|
| LeukocytosisBlood and lymphatic system disorders | 2/6 | 1/6 | 1/6 | 0/6 |
| AnaemiaBlood and lymphatic system disorders | 0/6 | 0/6 | 1/6 | 1/6 |
| ThrombocytopeniaBlood and lymphatic system disorders | 1/6 | 0/6 | 0/6 | 1/6 |
| Abdominal painGastrointestinal disorders | 1/6 | 1/6 | 0/6 | 0/6 |
| NauseaGastrointestinal disorders | 1/6 | 0/6 | 0/6 | 1/6 |
| Decreased appetiteMetabolism and nutrition disorders | 1/6 | 0/6 | 0/6 | 1/6 |
| Rash maculo-papularSkin and subcutaneous tissue disorders | 1/6 | 1/6 | 0/6 | 0/6 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 0/6 | 1/6 | 0/6 | 0/6 |
| Age, Categorical(Participants) | Part 1: ASLAN003 100mg QD | Part 1: ASLAN003 200mg QD | Part 1: ASLAN003 100mg BID | Part 1: ASLAN003 200mg BID | Total |
|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 4 | 2 | 0 | 2 | 8 |
| >=65 years | 2 | 4 | 6 | 4 | 16 |
| Sex: Female, Male(Participants) | Part 1: ASLAN003 100mg QD | Part 1: ASLAN003 200mg QD | Part 1: ASLAN003 100mg BID | Part 1: ASLAN003 200mg BID | Total |
|---|---|---|---|---|---|
| Female | 4 | 0 | 4 | 2 | 10 |
| Male | 2 | 6 | 2 | 4 | 14 |
| Race/Ethnicity, Customized(Participants) | Part 1: ASLAN003 100mg QD | Part 1: ASLAN003 200mg QD | Part 1: ASLAN003 100mg BID | Part 1: ASLAN003 200mg BID | Total |
|---|---|---|---|---|---|
| Caucasian | 1 | 5 | 5 | 4 | 15 |
| Asian | 5 | 1 | 1 | 1 | 8 |
| Other | 0 | 0 | 0 | 1 | 1 |
| Not Hispanic or Latino | 6 | 6 | 6 | 6 | 24 |
| Region of Enrollment(participants) | Part 1: ASLAN003 100mg QD | Part 1: ASLAN003 200mg QD | Part 1: ASLAN003 100mg BID | Part 1: ASLAN003 200mg BID | Total |
|---|---|---|---|---|---|
| Singapore | 4 | 1 | 1 | 1 | 7 |
| Australia | 2 | 5 | 5 | 5 | 17 |
| Height(CM) | Part 1: ASLAN003 100mg QD | Part 1: ASLAN003 200mg QD | Part 1: ASLAN003 100mg BID | Part 1: ASLAN003 200mg BID | Total |
|---|---|---|---|---|---|
| Mean | 162.67 ± 8.189 | 173.25 ± 7.640 | 158.17 ± 9.827 | 164.17 ± 7.627 | 164.56 ± 9.604 |
| Weight(KG) | Part 1: ASLAN003 100mg QD | Part 1: ASLAN003 200mg QD | Part 1: ASLAN003 100mg BID | Part 1: ASLAN003 200mg BID | Total |
|---|---|---|---|---|---|
| Mean | 53.00 ± 13.549 | 82.32 ± 11.216 | 63.82 ± 16.551 | 81.72 ± 21.244 | 70.21 ± 9.637 |
| BMI(kg/m^2) | Part 1: ASLAN003 100mg QD | Part 1: ASLAN003 200mg QD | Part 1: ASLAN003 100mg BID | Part 1: ASLAN003 200mg BID | Total |
|---|---|---|---|---|---|
| Mean | 19.855 ± 3.9883 | 27.368 ± 2.6446 | 25.065 ± 3.9042 | 30.553 ± 8.8254 | 25.710 ± 6.4119 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jan 2018 to primary completion in Sep 2019, 20 months.
Results were first posted in Jul 2021, 1 year 9 months after primary completion.
Of 385 non-industry phase 2 interventional studies under Leukemia, Myeloid, Acute, half reached primary completion within 66 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 107. This study's 20 months is below that.
Counting every sponsor, half of 442 studies reached it within 60 months; a quarter within 38 and three quarters within 104.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Farudodstat
ASLAN Pharmaceuticals